Table 2 Univariate analysis for progression-free survival of early progress
From: Risk factors for early progression of diffuse low-grade glioma in adults
Variable | PFS ≤ 60 months (n = 68) | PFS > 60 months (n = 70) | χ2/Z | p-Value |
|---|---|---|---|---|
Sex, n (%) | 0.113 | 0.737 | ||
Male | 34 (50.0) | 33 (47.1) | ||
Female | 34 (50.0) | 37 (52.9) | ||
Age, years, n (%) | 0.269 | 0.604 | ||
≥ 40 | 31 (45.6) | 35 (50.0) | ||
< 40 | 37 (54.4) | 35 (50.0) | ||
Tumor subtype, n (%) | 7.876 | 0.005 | ||
Astrocytoma | 54 (79.4) | 40 (57.1) | ||
Oligodendroglioma | 14 (20.6) | 30 (42.9) | ||
Tumor location, n (%) | 12.370 | 0.000 | ||
Superfical | 44 (64.7) | 63 (90.0) | ||
Deep | 24 (35.3) | 7 (10.0) | ||
Tumor range, n (%) | 6.521 | 0.011 | ||
Single lobe | 31 (45.6) | 47 (67.1) | ||
Multiple lobe | 37 (54.4) | 23 (32.9) | ||
Preoperative tumor volume, cm3, n (%) | 7.938 | 0.005 | ||
≤ 30 | 19 (27.9) | 36 (51.4) | ||
> 30 | 49 (72.1) | 34 (48.6) | ||
EOR, n (%) | −4.529a | 0.000 | ||
100 | 16 (23.5) | 46 (65.7) | ||
90–99 | 38 (55.9) | 18 (25.7) | ||
< 90 | 14 (20.6) | 6 (8.6) | ||
Treatment after first surgery, n (%) | 1.796 | 6.616 | ||
RT alone | 10 (14.7) | 10 (14.3) | ||
Chemotherapy alone | 15 (22.1) | 10 (14.3) | ||
RT + chemotherapy | 29 (42.6) | 31 (44.3) | ||
None | 14 (20.6) | 19 (27.1) |